Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort Secondary analyses from CALGB/SWOG 80405 provide insight into treatment paradigms for patients ...

CHICAGO — June 5, 2017 — For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life ...

Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management Center (SDMC) ...

Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), will share results of ...

SWOG Clinical Trials Partnerships (SWOG CTP) has signed a collaborative research agreement with Novartis Pharmaceuticals Corporation to form a strategic alliance via our Preferred Partnership Program ...

Cross institutional comparison of the miR-371a-3p assay in pre-surgical germ cell tumor (GCT) patients. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP ...

Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone ...

JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a >40% reduction in risk of death, whereas Signatera-negative patients ...

Natera (NTRA) announced the publication of findings from the randomized, phase III CALGB/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...